We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$244M
1-Year Est. Return
80.12%
This Fund
S&P 500
This Quarter
Est. Return
+19.47%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$274M
AUM Growth
-$8.51M
(-3%)
Cap. Flow
-$34.5M
Cap. Flow
% of AUM
-12.58%
Top 10 Holdings %
Top 10 Hldgs %
62.94%
Holding
42
New
5
Increased
7
Reduced
7
Closed
5
Top Buys
| 1 |
Replimune Group
REPL
|
+$12M |
| 2 |
ArriVent BioPharma
AVBP
|
+$4.49M |
| 3 |
Fennec Pharmaceuticals
FENC
|
+$4.41M |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$3.86M |
| 5 |
Xeris Biopharma Holdings
XERS
|
+$2.49M |
Top Sells
| 1 |
Rezolute
RZLT
|
+$14.2M |
| 2 |
Cytokinetics
CYTK
|
+$12.7M |
| 3 |
VRNA
Verona Pharma
VRNA
|
+$10.7M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$9.52M |
| 5 |
Fractyl Health
GUTS
|
+$7.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Delcath Systems
DCTH
$445M
| $33M | 12.02% |
3,300,389
| – | – |
|
2
Savara
SVRA
$1.15B
| $20.5M | 7.48% |
3,403,721
-596,279
| -15% | -$2.92M |
|
|
3
Fennec Pharmaceuticals
FENC
$389M
| $20.1M | 7.33% |
2,613,508
+536,668
| +26% | +$4.41M |
|
|
4
Xeris Biopharma Holdings
XERS
$1.42B
| $16.6M | 6.04% |
2,111,700
+315,934
| +18% | +$2.49M |
|
5
Viridian Therapeutics
VRDN
$2.08B
| $14M | 5.1% |
450,000
-150,000
| -25% | -$4.11M |
|
6
MediWound
MDWD
$186M
| $13.8M | 5.04% |
749,054
| – | – |
|
7
Verastem
VSTM
$476M
| $13.8M | 5.03% |
1,788,475
-141,088
| -7% | -$1.26M |
|
|
8
Replimune Group
REPL
$792M
| $13.7M | 5% |
+1,410,497
| New | +$12M |
|
|
ATYR
9
aTyr Pharma
ATYR
$50.9M
| $13.6M | 4.96% |
1,039,080
| – | – |
|
|
HELP
10
Cybin Inc
HELP
$413M
| $13.6M | 4.94% |
1,657,540
+157,540
| +11% | +$1.01M |
|
11
EyePoint Inc
EYPT
$1.13B
| $12.6M | 4.59% |
690,000
+40,000
| +6% | +$567K |
|
12
CG Oncology
CGON
$6.24B
| $12.5M | 4.54% |
300,000
| – | – |
|
|
13
Cytokinetics
CYTK
$10.9B
| $12.4M | 4.52% |
195,045
-204,955
| -51% | -$12.7M |
|
|
14
X4 Pharmaceuticals
XFOR
$375M
| $10.4M | 3.8% |
2,605,920
+1,061,313
| +69% | +$3.86M |
|
|
DFTX
15
Definium Therapeutics
DFTX
$6.04B
| $10M | 3.66% |
750,000
| – | – |
|
|
PROF
16
Profound Medical
PROF
$260M
| $8.41M | 3.07% |
1,068,955
+376,770
| +54% | +$2.42M |
|
17
InspireMD
NSPR
$33.3M
| $6.95M | 2.53% |
3,905,743
| – | – |
|
18
Ocular Therapeutix
OCUL
$2.08B
| $4.86M | 1.77% |
400,000
| – | – |
|
|
19
ArriVent BioPharma
AVBP
$1.51B
| $4.34M | 1.58% |
+215,871
| New | +$4.49M |
|
20
Talphera
TLPH
$72.7M
| $4.08M | 1.49% |
3,579,273
-806,484
| -18% | -$972K |
|
21
Myomo
MYO
$44M
| $3.49M | 1.27% |
3,839,772
+48,984
| +1% | +$47K |
|
22
PolyPid
PYPD
$102M
| $3.02M | 1.1% |
696,556
-222,112
| -24% | -$825K |
|
|
OKUR
23
OnKure Therapeutics
OKUR
$171M
| $2.12M | 0.77% |
+730,488
| New | +$2.19M |
|
|
RGNT
24
Regentis Biomaterials
RGNT
$17.8M
| $1.7M | 0.62% |
+251,510
| New | +$1.73M |
|
25
Trevi Therapeutics
TRVI
$2.49B
| $1.25M | 0.46% |
100,000
| – | – |
|
Similar funds
AWG
BNMT
CA
BB
GIM
IAMOG
AWM
OCFG